CDC finds lower RSV hospitalization rates for infants receiving prevention products
The Centers for Disease Control and Prevention May 8 released an analysis that found declines in hospitalizations for infants infected with respiratory syncytial virus during the 2024-2025 RSV season — the first with widespread availability of the maternal RSV vaccine and nirsevimab, a long-acting monoclonal antibody. Rates were 45% to 52% lower for infants less than 3 months old and 28% to 43% lower for those less than 8 months old. As of February, an estimated 66% of infants received either the maternal RSV vaccine or nirsevimab during the 2024-2025 season.
Related News Articles
Headline
Vickie Johnson, executive vice president and chief community officer at Cleveland Clinic, and Roopa Thakur, M.D., pediatrician and associate program director…
Headline
Elizabeth Dabrowski, M.D., pediatric endocrinologist at Children’s Wisconsin, and Matthew Edwards, R.D., diabetes care and education specialist at Children’s…
Headline
The Food and Drug Administration Nov. 8 announced it is investigating an outbreak of 13 infant botulism illnesses in 10 states. The agency said all cases were…
Headline
The AHA collaborated with LCMC Health in New Orleans to spotlight innovative efforts that extend care beyond hospital walls. LCMC Health supports families…
Headline
A collaborative program between Rush University Medical Center and the University of Wisconsin-Milwaukee brings fathers into the prenatal care program and…
Headline
The White House Sept. 9 released its “Make Our Children Healthy Again” strategy report, created to address childhood chronic diseases. The report highlights…